Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma.
作者信息
Krejcik Jakub, van de Donk Niels W C J
机构信息
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.
出版信息
Oncotarget. 2018 Sep 14;9(72):33621-33622. doi: 10.18632/oncotarget.26098.
Abstract
摘要
相似文献
1
Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma.
Oncotarget. 2018 Sep 14;9(72):33621-33622. doi: 10.18632/oncotarget.26098.
2
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
Haematologica. 2011 Feb;96(2):284-90. doi: 10.3324/haematol.2010.030759. Epub 2010 Nov 25.
3
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
Cells. 2020 Feb 6;9(2):378. doi: 10.3390/cells9020378.
4
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27.
5
Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Biochem Biophys Res Commun. 2021 Jan 15;536:26-31. doi: 10.1016/j.bbrc.2020.12.048. Epub 2020 Dec 22.
6
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.
7
Daratumumab for the treatment of multiple myeloma.
Expert Opin Biol Ther. 2017 Jul;17(7):887-893. doi: 10.1080/14712598.2017.1322578. Epub 2017 May 2.
8
Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by -Expanded Autologous NK Cells.
Clin Cancer Res. 2018 Aug 15;24(16):4006-4017. doi: 10.1158/1078-0432.CCR-17-3117. Epub 2018 Apr 17.
9
CD38-specific nanobodies allow imaging of multiple myeloma under daratumumab therapy.
Front Immunol. 2022 Oct 27;13:1010270. doi: 10.3389/fimmu.2022.1010270. eCollection 2022.
10
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
Radiology. 2020 Jun;295(3):606-615. doi: 10.1148/radiol.2020192621. Epub 2020 Apr 7.
引用本文的文献
1
Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery.
Cancers (Basel). 2024 May 13;16(10):1854. doi: 10.3390/cancers16101854.
2
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.
J Hematol Oncol. 2022 Feb 16;15(1):17. doi: 10.1186/s13045-022-01234-2.
3
Harnessing the Immune System to Fight Multiple Myeloma.
Cancers (Basel). 2021 Sep 10;13(18):4546. doi: 10.3390/cancers13184546.
4
High expression of CD38 and MHC class II on CD8 T cells during severe influenza disease reflects bystander activation and trogocytosis.
Clin Transl Immunology. 2021 Sep 8;10(9):e1336. doi: 10.1002/cti2.1336. eCollection 2021.
5
Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.
J Clin Med. 2020 Apr 22;9(4):1195. doi: 10.3390/jcm9041195.
6
The CD38 natural killer cell line KHYG1 transiently expressing CD16 in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide.
Cancer Immunol Immunother. 2020 Mar;69(3):421-434. doi: 10.1007/s00262-019-02477-8. Epub 2020 Jan 9.
7
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
Haematologica. 2020 Apr;105(4):1032-1041. doi: 10.3324/haematol.2018.211904. Epub 2019 Jul 11.
8
CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.
Front Immunol. 2019 Apr 24;10:760. doi: 10.3389/fimmu.2019.00760. eCollection 2019.
本文引用的文献
1
CD38 antibodies in multiple myeloma: back to the future.
Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8.
2
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Clin Cancer Res. 2017 Dec 15;23(24):7498-7511. doi: 10.1158/1078-0432.CCR-17-2027. Epub 2017 Oct 12.
3
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
Clin Cancer Res. 2017 Mar 15;23(6):1493-1505. doi: 10.1158/1078-0432.CCR-15-2095. Epub 2016 Sep 16.
4
Microenvironment drug resistance in multiple myeloma: emerging new players.
Oncotarget. 2016 Sep 13;7(37):60698-60711. doi: 10.18632/oncotarget.10849.
5
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.
6
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.
7
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27.
Zotero 插件